The measures, which will be carried out over the next three to five years, will include the closures of two sites in Switzerland and one in Italy. It will also involve moving some research activities out of Switzerland and to the United States.
Continue Reading Below
Novartis said it would take a restructuring charge of around $300 million in the fourth quarter.
(Reporting by Katie Reid)